Cargando…

1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico

BACKGROUND: Tuberculosis (TB) is the leading cause of death from a single infectious agent. Latent tuberculosis infection (LTBI) is defined as TB infection without clinical symptoms or microbiological evidence. LTBI is a risk factor to later development of active TB. COVID-19 pandemic represents an...

Descripción completa

Detalles Bibliográficos
Autores principales: Montiel, Santiago, Valente-Acosta, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677184/
http://dx.doi.org/10.1093/ofid/ofad500.1714
_version_ 1785150070188933120
author Montiel, Santiago
Valente-Acosta, Benjamin
author_facet Montiel, Santiago
Valente-Acosta, Benjamin
author_sort Montiel, Santiago
collection PubMed
description BACKGROUND: Tuberculosis (TB) is the leading cause of death from a single infectious agent. Latent tuberculosis infection (LTBI) is defined as TB infection without clinical symptoms or microbiological evidence. LTBI is a risk factor to later development of active TB. COVID-19 pandemic represents an emerging infectious disease. Immunosuppressants as corticoids and tocilizumab are the standard of care of critically ill COVID-19 patients. Those drugs have previously been shown to increase the risk of developing active TB, especially in patients with latent TB. [Figure: see text] METHODS: We conduct a cross-sectional study to determine the prevalence of latent tuberculosis infection, through QuantiFERON, in patients who have been hospitalized with severe or critical COVID-19 at the ABC Medical Center in Mexico City-Mexico, from March 2020 to March 2021. RESULTS: From 1174 records reviewed, a total of 503 patients who have a QuantiFERON® test were included. The prevalence of LTBI in hospitalized patients with severe or critical COVID-19 in our hospital was 10.1% (n=51). Of the total of patients with a diagnosis of LTBI, 82.3% had severe disease and 17.6% had critical illness requiring invasive mechanical ventilation (IMV) and 42 (82%) received corticosteroids and 29 (57%) received tocilizumab. CONCLUSION: To the best of our knowledge this is the first report that depict the LTBI prevalence in a cohort of severe and critical COVID-19 patients in a Lower-Middle Income Country. Our prevalence was lower than previously reported global prevalence of LTBI. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677184
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106771842023-11-27 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico Montiel, Santiago Valente-Acosta, Benjamin Open Forum Infect Dis Abstract BACKGROUND: Tuberculosis (TB) is the leading cause of death from a single infectious agent. Latent tuberculosis infection (LTBI) is defined as TB infection without clinical symptoms or microbiological evidence. LTBI is a risk factor to later development of active TB. COVID-19 pandemic represents an emerging infectious disease. Immunosuppressants as corticoids and tocilizumab are the standard of care of critically ill COVID-19 patients. Those drugs have previously been shown to increase the risk of developing active TB, especially in patients with latent TB. [Figure: see text] METHODS: We conduct a cross-sectional study to determine the prevalence of latent tuberculosis infection, through QuantiFERON, in patients who have been hospitalized with severe or critical COVID-19 at the ABC Medical Center in Mexico City-Mexico, from March 2020 to March 2021. RESULTS: From 1174 records reviewed, a total of 503 patients who have a QuantiFERON® test were included. The prevalence of LTBI in hospitalized patients with severe or critical COVID-19 in our hospital was 10.1% (n=51). Of the total of patients with a diagnosis of LTBI, 82.3% had severe disease and 17.6% had critical illness requiring invasive mechanical ventilation (IMV) and 42 (82%) received corticosteroids and 29 (57%) received tocilizumab. CONCLUSION: To the best of our knowledge this is the first report that depict the LTBI prevalence in a cohort of severe and critical COVID-19 patients in a Lower-Middle Income Country. Our prevalence was lower than previously reported global prevalence of LTBI. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677184/ http://dx.doi.org/10.1093/ofid/ofad500.1714 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Montiel, Santiago
Valente-Acosta, Benjamin
1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico
title 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico
title_full 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico
title_fullStr 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico
title_full_unstemmed 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico
title_short 1886. Prevalence Of Latent TB Infection Among Critically Ill COVID-19 Population In a Tertiary Teaching Hospital In Mexico
title_sort 1886. prevalence of latent tb infection among critically ill covid-19 population in a tertiary teaching hospital in mexico
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677184/
http://dx.doi.org/10.1093/ofid/ofad500.1714
work_keys_str_mv AT montielsantiago 1886prevalenceoflatenttbinfectionamongcriticallyillcovid19populationinatertiaryteachinghospitalinmexico
AT valenteacostabenjamin 1886prevalenceoflatenttbinfectionamongcriticallyillcovid19populationinatertiaryteachinghospitalinmexico